Taleb H. Al-Tel, Amarnath Reddy, Raafat El-Awady, Varsha M. Menon, Srinivasulu Vunnam, Ralph Mazitschek and Imad Abu Yousef
Sharjah Institute for Medical Research and College of Pharmacy, University of Sharjah, Sharjah, UAE
The success of drug discovery requires a good starting chemical point. The engine powering of such a point is driven by development of efficient synthetic strategies that lead to a chemical space of skeletally diverse and privileged motifs. Among others is phenotypic screening of libraries delivered from privileged diversity-oriented synthesis (pDOS). Therefore, the key challenge has become how to design and synthesize privileged small-molecule libraries possessing molecular complexity and the attributes of drug like scaffolds. In this respect, we envisioned that, examples of pDOS-derived frameworks as in Fig. 1, could serve as chemical "navigators" toward biologically relevant chemical spaces. Therefore, in this presentation, the focus will be shifted toward the design of quality compounds with privileged structures (Fig. 1). Furthermore, preliminary biological studies indicated that these privileged molecular architectures posses the attributes as potential anticancer and antimalarial lead candidates.
Figure 1: Synthesis of Novel Libraries of Privileged and complex molecular architectures.